ISRCTN73274643 https://doi.org/10.1186/ISRCTN73274643

Non-Hodgkins lymphoma T-cell protocol

Submission date 01/07/2001	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [ ] Record updated in last year
Registration date 01/07/2001	**Overall study status** Completed	
Last Edited 23/02/2015	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
- - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NHL9503

Study information

Scientific Title

Non-Hodgkins lymphoma T-cell protocol

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Lymphoma (non-Hodgkin's)

Interventions
1. Group A: Chemotherapy including third intensification block at 35 weeks
2. Group B: Chemotherapy without third intensification block at 35 weeks

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date

01/01/1997

Completion date
28/02/2000

Eligibility

Key inclusion criteria
1. T-cell non-Hodgkin's lymphoma
2. Stages I-IV
3. Confirmed remission achieved
4. Less than 25% blasts in bone marrow
5. No circulating blasts in blood
6. Aged <18 years

Participant type(s)
Patient

Age group
Child

Upper age limit
18 Years

Sex
Both

Target number of participants
Not provided at time of registration

Key exclusion criteria
Patients with T-cell anaplastic lymphoma or peripheral T-cell lymphoma are excluded.

Date of first enrolment
01/01/1997

Date of final enrolment
28/02/2000

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

Sponsor details
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type
Charity

Website
http://www.cancer.org.uk

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Funder Name
United Kingdom Children's Cancer Study Group (UKCCSG)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration